• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MET 融合和剪接变异是异柠檬酸脱氢酶突变型星形细胞瘤的一个强烈不良预后因素。

MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.

机构信息

Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

出版信息

Brain Pathol. 2024 May;34(3):e13198. doi: 10.1111/bpa.13198. Epub 2023 Aug 2.

DOI:10.1111/bpa.13198
PMID:37530224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11007006/
Abstract

Liu et al. describe the adverse prognostic role of MET fusions and splicing variants in astrocytoma, isocitrate dehydrogenase mutant. On this basis, MET fusions and splicing variants was suggested to be a biomarker for the diagnosis of high-grade astrocytoma, isocitrate dehydrogenase mutant.

摘要

刘等人描述了 MET 融合和剪接变异在星形细胞瘤、异柠檬酸脱氢酶突变体中的不良预后作用。在此基础上，MET 融合和剪接变异被建议作为高级别星形细胞瘤、异柠檬酸脱氢酶突变体的诊断标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d8c/11007006/ffe4a37efbe8/BPA-34-e13198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d8c/11007006/ffe4a37efbe8/BPA-34-e13198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d8c/11007006/ffe4a37efbe8/BPA-34-e13198-g001.jpg

相似文献

1
MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.MET 融合和剪接变异是异柠檬酸脱氢酶突变型星形细胞瘤的一个强烈不良预后因素。
Brain Pathol. 2024 May;34(3):e13198. doi: 10.1111/bpa.13198. Epub 2023 Aug 2.
2
An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.基于世界卫生组织中枢神经系统肿瘤分类第5版的异柠檬酸脱氢酶突变型4级星形细胞瘤分析：对临床实践的启示
Ann Clin Transl Neurol. 2025 Jul;12(7):1442-1453. doi: 10.1002/acn3.70081. Epub 2025 May 21.
3
Supratotal Resection Versus Gross Total Resection for Isocitrate Dehydrogenase-Wildtype Glioblastoma and Grade 4 Isocitrate Dehydrogenase-Mutant Astrocytoma: Meta-Analysis of Individual Patient Data.异柠檬酸脱氢酶野生型胶质母细胞瘤和4级异柠檬酸脱氢酶突变型星形细胞瘤的次全切除与全切除：个体患者数据的荟萃分析
Oper Neurosurg (Hagerstown). 2024 Nov 18. doi: 10.1227/ons.0000000000001434.
4
Presence of Fragmented Intratumoral Thrombosed Microvasculature in the Necrotic and Peri-Necrotic Regions on SWI Differentiates IDH Wild-Type Glioblastoma From IDH Mutant Grade 4 Astrocytoma.磁敏感加权成像（SWI）上坏死及坏死周边区域存在瘤内破碎血栓形成的微血管，可将异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤与IDH突变型4级星形细胞瘤区分开来。
J Magn Reson Imaging. 2025 Jul;62(1):258-270. doi: 10.1002/jmri.29695. Epub 2025 Jan 9.
5
The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.CDKN2A/B半合子缺失在异柠檬酸脱氢酶（IDH）突变型胶质瘤中的预后影响
Neuro Oncol. 2025 Mar 7;27(3):743-754. doi: 10.1093/neuonc/noae238.
6
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.表观遗传景观重排和胚胎发育基因的重新激活与 IDH 突变型星形细胞瘤的恶性转化有关。
Acta Neuropathol. 2024 Oct 9;148(1):50. doi: 10.1007/s00401-024-02811-0.
7
Predicting the molecular subtypes of 2021 WHO grade 4 glioma by a multiparametric MRI-based machine learning model.基于多参数磁共振成像的机器学习模型预测2021年世界卫生组织4级胶质瘤的分子亚型
BMC Cancer. 2025 Jul 14;25(1):1171. doi: 10.1186/s12885-025-14529-7.
8
Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis.复发性星形细胞瘤中的双重表型，IDH 突变型；IDH 突变型和 IDH 野生型成分共存：一例伴有遗传和表观遗传分析的病例报告。
Acta Neuropathol Commun. 2024 Oct 26;12(1):169. doi: 10.1186/s40478-024-01879-9.
9
Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.遗传和表观遗传不稳定性是 IDH 突变型星形细胞瘤进展和侵袭性行为的潜在驱动因素。
Acta Neuropathol. 2024 Jul 16;148(1):5. doi: 10.1007/s00401-024-02761-7.
10
Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young.55岁及以上人群中的异柠檬酸脱氢酶突变型星形细胞瘤：与年轻人相比的生存差异
J Neuropathol Exp Neurol. 2025 Jul 1;84(7):611-616. doi: 10.1093/jnen/nlaf024.

引用本文的文献

1
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.异柠檬酸脱氢酶（IDH）突变型星形细胞瘤的纵向分析揭示了与较差生存率相关的获得性RAS-丝裂原活化蛋白激酶（MAPK）通路突变。
Neurooncol Adv. 2025 Jan 29;7(1):vdaf024. doi: 10.1093/noajnl/vdaf024. eCollection 2025 Jan-Dec.

本文引用的文献

1
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.异柠檬酸脱氢酶（IDH）突变型脑胶质瘤：神经肿瘤学会（SNO）关于诊断、管理和未来方向的共识综述。
Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.
2
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.美国 2014-2018 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105. doi: 10.1093/neuonc/noab200.
3
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
4
Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients.中国脑胶质瘤基因组图谱（CGGA）：来自中国脑胶质瘤患者的功能基因组数据的综合资源。
Genomics Proteomics Bioinformatics. 2021 Feb;19(1):1-12. doi: 10.1016/j.gpb.2020.10.005. Epub 2021 Mar 2.
5
Clinical practice guidelines for the management of adult diffuse gliomas.成人弥漫性胶质瘤治疗的临床实践指南。
Cancer Lett. 2021 Feb 28;499:60-72. doi: 10.1016/j.canlet.2020.10.050. Epub 2020 Nov 6.
6
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
7
Identification of subsets of -mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks.鉴定具有不同表观遗传和拷贝数改变以及分层临床风险的 - 突变胶质母细胞瘤亚群。
Neurooncol Adv. 2019 May-Dec;1(1):vdz015. doi: 10.1093/noajnl/vdz015. Epub 2019 Jul 17.
8
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.继发性胶质母细胞瘤的突变特征指导脑肿瘤中针对 MET 的靶向试验。
Cell. 2018 Nov 29;175(6):1665-1678.e18. doi: 10.1016/j.cell.2018.09.038. Epub 2018 Oct 18.
9
Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.在高级别胶质瘤中鉴定出一种导致细胞内蛋白自激活的新型MET突变。
Acta Neuropathol. 2015 Jul;130(1):131-44. doi: 10.1007/s00401-015-1420-5. Epub 2015 Apr 11.